Triazolopyridinyl compounds as kinase inhibitors

US12110290B2 · kind B2 · utility

Assignee

• Bristol-Myers Squibb Company · US

Inventors

• Guanglin Luo · Newtown, US
• Jie Chen · Houston, US
• Carolyn Diane Dzierba · Middletown, US
• David B. Frennesson · Naugatuck, US
• Junqing Guo · Princeton, US
• Amy C. Hart · Ewing, US
• Xirui Hu · Cambridge, US
• Michael E. Mertzman · New Hope, US
• Matthew Reiser Patton · Cambridge, US
• Jianliang Shi · Furlong, US
• Steven H. Spergel · Warrington, US
• Brian Lee Venables · Durham, US
• Yong-Jin Wu · Madison, US
• Zili Xiao · Plainsboro, US
• Michael G. Yang · Narberth, US

Key dates

• Filing date: Jul 6, 2023
• Grant date: Oct 8, 2024
• Expiry date: Jul 6, 2043

Classification

• Technology area (CPC A): Human Necessities
• CPC primary: A61P29/00
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

Compounds having formula (I), and enantiomers, and diastereomers, stereoisomers, pharmaceutically-acceptable salts thereof, are useful as kinase modulators, including RIPK1 modulation. All the variables are as defined herein.